Our patients have the opportunity to participate in a wide variety of clinical trials of novel therapies, including both drug and adjunctive treatments. We also conduct studies that test biomarkers and diagnostic tests. Many of our faculty are also active in trial development and design. A large focus has been on vasculitis and scleroderma trials to date, with an expansion to other disease areas now including gout and osteoarthritis. Recent examples of trials in scleroderma have included agents to treat pulmonary hypertension, digital ulcers, lung disease, skin fibrosis and overall disease therapy. Our program is an active member of the Scleroderma Clinical Trials Consortium (SCTC), an international group that conducts multicenter trials of therapies in scleroderma. We are also actively enrolling interested patients in a variety of ongoing studies to assess clinical and biologic outcomes in a variety of rheumatic diseases.
Our programs also serve as important educational hub for other physicians and trainees to enhance awareness and clinical care in rheumatic diseases.
Active trials change frequently, so please contact us directly for questions about enrolling trials.